Update on the role of neutrophils in atherosclerotic plaque vulnerability

Current Drug Targets

Volumn 16, Issue 4, 2015, Pages 321-333

  Carbone, Federico ^a,b   Mach, François ^a   Montecucco, Fabrizio ^a,b,c  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Atherosclerosis; Inflammation; Matrix metalloproteinase; Myeloperoxidase; Neutrophil; Vulnerable plaque

Indexed keywords

ALPHA DEFENSIN; CD18 ANTIGEN; CD40 LIGAND; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR2; COLLAGENASE; CREATINE KINASE; CXCL1 CHEMOKINE; DECORIN; ELASTASE; FIBRONECTIN; GELATINASE; GELATINASE A; GELATINASE B; INTERLEUKIN 8; INTERLEUKIN RECEPTOR; LAMININ; MATRIX METALLOPROTEINASE; MYELOPEROXIDASE; N [4 [[[6, 7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL] CARBONYL] AMINO] BENZYL] N, N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NEUTROPHIL COLLAGENASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; P SELECTIN GLYCOPROTEIN LIGAND 1; PROTEOGLYCAN; RANTES; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VITRONECTIN; ANTIINFLAMMATORY AGENT; CARDIOVASCULAR AGENT;

APOPTOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; DRUG TARGETING; EXTRACELLULAR TRAP; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; NEUTROPHIL; NEUTROPHIL COUNT; NEUTROPHIL GRANULE; OUTCOME ASSESSMENT; ANIMAL; ARTERY; ATHEROSCLEROSIS; DISEASE COURSE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PATHOLOGY; RUPTURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTERIES; ATHEROSCLEROSIS; CARDIOVASCULAR AGENTS; DISEASE PROGRESSION; HUMANS; NEUTROPHIL ACTIVATION; NEUTROPHILS; PLAQUE, ATHEROSCLEROTIC; RUPTURE, SPONTANEOUS;

EID: 84928893734     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666141110093013     Document Type: Article

References (166)

1. [1] Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32(9): 2045-51.
2. [2] Yamashiro S, Kamohara H, Wang JM, Yang D, Gong WH, Yoshimura T. Phenotypic and functional change of cytokine-activated neutrophils: inflammatory neutrophils are heterogeneous and enhance adaptive immune responses. J Leukoc Biol 2001; 69(5): 698-704.
3. [3] Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol 2008; 83(1): 64-70.
4. [4] Hosokawa T, Kumon Y, Kobayashi T, et al. Neutrophil infiltration and oxidant-production in human atherosclerotic carotid plaques. Histol Histopathol 2011; 26(1): 1-11.
5. [5] Hurtado-Nedelec M, Makni-Maalej K, Gougerot-Pocidalo MA, Dang PM, El-Benna J. Assessment of priming of the human neutrophil respiratory burst. Methods Mol Biol 2014; 1124 405-12.
6. [6] Lee A, Whyte MK, Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol 1993; 54(4): 283-8.
7. [7] Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002; 106(23): 2894-900.
8. 8[] Paulsson J, Dadfar E, Held C, Jacobson SH, Lundahl J. Activation of peripheral and in vivo transmigrated neutrophils in patients with stable coronary artery disease. Atherosclerosis 2007; 192(2): 328-34.
9. [9] Levy D. Combating the epidemic of heart disease. Jama 2012; 308(24): 2624-5.
10. [10] Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010; 30(7): 1282-92.
11. [11] Krams R, Cheng C, Helderman F, et al. Shear stress is associated with markers of plaque vulnerability and MMP-9 activity. EuroIntervention 2006; 2(2): 250-6.
12. [12] Shah PK. Inflammation and plaque vulnerability. Cardiovasc Drugs Ther 2009; 23(1): 31-40.
13. [13] Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108(14): 1664-72.
14. [14] Sasaki T, Kuzuya M, Nakamura K, et al. A simple method of plaque rupture induction in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26(6): 1304-9.
15. [15] Ionita MG, van den Borne P, Catanzariti LM, et al. High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol 2010; 30(9): 1842-8.
16. [16] Mazzone A, De Servi S, Ricevuti G, et al. Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation 1993; 88(2): 358-63.
17. [17] Grau AJ, Boddy AW, Dukovic DA, et al. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 2004; 35(5): 1147-52.
18. [18] Pinto EM, Huppert FA, Morgan K, Mrc C, Brayne C. Neutrophil counts, monocyte counts and cardiovascular disease in the elderly. Exp Gerontol 2004; 39(4): 615-9.
19. [19] Gillum RF, Mussolino ME, Madans JH. Counts of neutrophils, lymphocytes, and monocytes, cause-specific mortality and coronary heart disease: the NHANES-I epidemiologic follow-up study. Ann Epidemiol 2005; 15(4): 266-71.
20. [20] Haumer M, Amighi J, Exner M, et al. Association of neutrophils and future cardiovascular events in patients with peripheral artery disease. J Vasc Surg 2005; 41(4): 610-7.
21. [21] Nijm J, Wikby A, Tompa A, Olsson AG, Jonasson L. Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease. Am J Cardiol 2005; 95(4): 452-6.
22. [22] Tsai JC, Sheu SH, Chiu HC, et al. Association of peripheral total and differential leukocyte counts with metabolic syndrome and risk of ischemic cardiovascular diseases in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2007; 23(2): 111-8.
23. [23] O'Donoghue M, Morrow DA, Cannon CP, et al. Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. Eur Heart J 2008; 29(8): 984-91.
24. [24] Takahashi T, Hiasa Y, Ohara Y, et al. Relationship of admission neutrophil count to microvascular injury, left ventricular dilation, and long-term outcome in patients treated with primary angioplasty for acute myocardial infarction. Circ J 2008; 72(6): 867-72.
25. [25] Toor IS, Jaumdally RJ, Moss MS, Babu SB. Preprocedural neutrophil count predicts outcome in patients with advanced peripheral vascular disease undergoing percutaneous transluminal angioplasty. J Vasc Surg 2008; 48(6): 1504-8.
26. [26] Li DB, Hua Q, Liu Z, et al. Association between inflammatory mediators and angiographic morphologic features indicating thrombus formation in patients with acute myocardial infarction. Chin Med J (Engl) 2009; 122(15): 1738-42.
27. [27] Huang G, Zhong XN, Zhong B, et al. Significance of white blood cell count and its subtypes in patients with acute coronary syndrome. Eur J Clin Invest 2009; 39(5): 348-58.
28. [28] Setianto BY, Hartopo AB, Gharini PP, Anggrahini DW, Irawan B. Circulating soluble CD40 ligand mediates the interaction between neutrophils and platelets in acute coronary syndrome. Heart Vessels 2010; 25(4): 282-7.
29. [29] Giugliano G, Brevetti G, Lanero S, Schiano V, Laurenzano E, Chiariello M. Leukocyte count in peripheral arterial disease: A simple, reliable, inexpensive approach to cardiovascular risk prediction. Atherosclerosis 2010; 210(1): 288-93.
30. [30] Lee HY, Kim JH, Kim BO, et al. Effect of Aspiration Thrombectomy on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction With an Elevated Neutrophil Count. Korean Circ J 2011; 41(2): 68-75.
31. [31] Angeli F, Angeli E, Ambrosio G, et al. Neutrophil count and ambulatory pulse pressure as predictors of cardiovascular adverse events in postmenopausal women with hypertension. Am J Hypertens 2011; 24(5): 591-8.
32. [32] o Hartaigh B, Bosch JA, Thomas GN, et al. Which leukocyte subsets predict cardiovascular mortality? From the LUdwigshafen RIsk and Cardiovascular Health (LURIC) Study. Atherosclerosis 2012; 224(1): 161-9.
33. [33] Tokgoz S, Kayrak M, Akpinar Z, Seyithanoglu A, Guney F, Yuruten B. Neutrophil lymphocyte ratio as a predictor of stroke. J Stroke Cerebrovasc Dis 2013; 22(7): 1169-74.
34. [34] Ozturk S, Erdem A, Ozlu MF, et al. Assessment of the neutrophil to lymphocyte ratio in young patients with acute coronary syndromes. Turk Kardiyol Dern Ars 2013; 41(4): 284-9.
35. [35] Mayer FJ, Gruenberger D, Schillinger M, et al. Prognostic value of neutrophils in patients with asymptomatic carotid artery disease. Atherosclerosis 2013; 231(2): 274-80.
36. [36] Horne BD, Anderson JL, John JM, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol 2005; 45(10): 1638-43.
37. [37] Zazula AD, Precoma-Neto D, Gomes AM, et al. An assessment of neutrophils/lymphocytes ratio in patients suspected of acute coronary syndrome. Arq Bras Cardiol 2008; 90(1): 31-6
38. [38] Papa A, Emdin M, Passino C, Michelassi C, Battaglia D, Cocci F. Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clin Chim Acta 2008; 395(1-2): 27-31.
39. [39] Arbel Y, Finkelstein A, Halkin A, et al. Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography. Atherosclerosis 2012; 225(2): 456-60.
40. [40] Sahin DY, Gur M, Elbasan Z, et al. Predictors of preinterventional patency of infarct-related artery in patients with ST-segment elevation myocardial infarction: Importance of neutrophil to lymphocyte ratio and uric acid level. Exp Clin Cardiol 2013; 18(2): e77-81.
41. [41] An X, Mao HP, Wei X, et al. Elevated neutrophil to lymphocyte ratio predicts overall and cardiovascular mortality in maintenance peritoneal dialysis patients. Int Urol Nephrol 2012; 44(5): 1521-8.
42. [42] Gary T, Pichler M, Belaj K, et al. Neutrophil-to-lymphocyte ratio and its association with critical limb ischemia in PAOD patients. PLoS One 2013; 8(2): e56745.
43. [43] Kaya MG, Akpek M, Lam YY, et al. Prognostic value of neutrophil/lymphocyte ratio in patients with ST-elevated myocardial infarction undergoing primary coronary intervention: a prospective, multicenter study. Int J Cardiol 2013; 168(2): 1154-9.
44. [44] Sen N, Afsar B, Ozcan F, et al. The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term adverse outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Atherosclerosis 2013; 228(1): 203-10.
45. [45] Han YC, Yang TH, Kim DI, et al. Neutrophil to Lymphocyte Ratio Predicts Long-Term Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Korean Circ J 2013; 43(2): 93-9.
46. [46] Solak Y, Yilmaz MI, Sonmez A, et al. Neutrophil to lymphocyte ratio independently predicts cardiovascular events in patients with chronic kidney disease. Clin Exp Nephrol 2013; 17(4): 532-40.
47. [47] Azab B, Chainani V, Shah N, McGinn JT. Neutrophil-lymphocyte ratio as a predictor of major adverse cardiac events among diabetic population: a 4-year follow-up study. Angiology 2013; 64(6): 456-65.
48. [48] Akil E, Akil MA, Varol S, et al. Echocardiographic Epicardial Fat Thickness and Neutrophil to Lymphocyte Ratio are Novel Inflammatory Predictors of Cerebral Ischemic Stroke. J Stroke Cerebrovasc Dis 2014, 23(9):2328-34.
49. [49] Erkol A, Oduncu V, Turan B, et al. Neutrophil to lymphocyte ratio in acute ST-segment elevation myocardial infarction. Am J Med Sci 2014; 348(1): 37-42.
50. [50] He J, Li J, Wang Y, Hao P, Hua Q. Neutrophil-to-lymphocyte ratio (NLR) predicts mortality and adverse-outcomes after ST-segment elevation myocardial infarction in Chinese people. Int J Clin Exp Pathol 2014; 7(7): 4045-56.
51. [51] Kurtul A, Murat SN, Yarlioglues M, et al. The relationship between neutrophil/lymphocyte ratio and infarct-related artery patency before mechanical reperfusion in patients with ST-elevation myocardial infarction. Coron Artery Dis 2014; 25(2): 159-66.
52. [52] Back M, Ketelhuth DF, Agewall S. Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 2010; 52(5): 410-28.
53. [53] Yabluchanskiy A, Ma Y, Iyer RP, Hall ME, Lindsey ML. Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. Physiology (Bethesda) 2013; 28(6): 391-403.
54. [54] Rao VH, Kansal V, Stoupa S, Agrawal DK. MMP-1 and MMP-9 regulate epidermal growth factor-dependent collagen loss in human carotid plaque smooth muscle cells. Physiol Rep 2014; 2(2): e00224.
55. [55] de Nooijer R, Verkleij CJ, von der Thusen JH, et al. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol 2006; 26(2): 340-6.
56. [56] Gough PJ, Gomez IG, Wille PT, Raines EW. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest 2006; 116(1): 59-69.
57. [57] Montecucco F, Vuilleumier N, Pagano S, et al. Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 2011; 32(4): 412-21.
58. [58] Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94(6): 2493-503.
59. [59] Montecucco F, Lenglet S, Gayet-Ageron A, et al. Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. Stroke 2010; 41(7): 1394-404.
60. [60] Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995; 91(8): 2125-31.
61. [61] Loftus IM, Naylor AR, Goodall S, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 2000; 31(1): 40-7.
62. [62] Stintzing S, Heuschmann P, Barbera L, et al. Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae, inflammation, and apoptosis. Ann Vasc Surg 2005; 19(3): 310-9.
63. [63] Heo SH, Cho CH, Kim HO, et al. Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: involvement of matrix metalloproteinases 2 and 9. J Clin Neurol 2011; 7(2): 69-76.
64. [64] Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001; 141(2): 211-7.
65. [65] Zeng B, Prasan A, Fung KC, et al. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J 2005; 35(6): 331-5.
66. [66] Fukuda D, Shimada K, Tanaka A, et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2006; 97(2): 175-80.
67. [67] Eldrup N, Gronholdt ML, Sillesen H, Nordestgaard BG. Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation 2006; 114(17): 1847-54
68. [68] Welsh P, Whincup PH, Papacosta O, et al. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. Qjm 2008; 101(10): 785-91
69. [69] Ye ZX, Leu HB, Wu TC, Lin SJ, Chen JW. Baseline serum matrix metalloproteinase-9 level predicts long-term prognosis after coronary revascularizations in stable coronary artery disease. Clin Biochem 2008; 41(4-5): 292-8
70. [70] Dhillon OS, Khan SQ, Narayan HK, et al. Matrix metalloproteinase-2 predicts mortality in patients with acute coronary syndrome. Clin Sci (Lond) 2010; 118(4): 249-57
71. [71] Jefferis BJ, Whincup P, Welsh P, et al. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis 2010; 208(2): 557-63
72. [72] Velagaleti RS, Gona P, Sundstrom J, et al. Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality. Arterioscler Thromb Vasc Biol 2010; 30(11): 2283-8
73. [73] Kobayashi N, Hata N, Kume N, et al. Matrix metalloproteinase-9 for the earliest stage acute coronary syndrome. Circ J 2011; 75(12): 2853-61
74. [74] Hansson J, Vasan RS, Arnlov J, et al. Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: cohort study. PLoS One 2011; 6(1): e16185
75. [75] Eldrup N, Kragelund C, Steffensen R, Nordestgaard BG. Prognosis by C-reactive protein and matrix metalloproteinase-9 levels in stable coronary heart disease during 15 years of follow-up. Nutr Metab Cardiovasc Dis 2012; 22(8): 677-83
76. [76] Wang KF, Huang PH, Chiang CH, et al. Usefulness of plasma matrix metalloproteinase-9 level in predicting future coronary revascularization in patients after acute myocardial infarction. Coron Artery Dis 2013; 24(1): 23-8
77. [77] Tuomainen AM, Nyyssonen K, Laukkanen JA, et al. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol 2007; 27(12): 2722-8
78. [78] Tuomainen AM, Kormi I, Havulinna AS, et al. Serum tissue-degrading proteinases and incident cardiovascular disease events. Eur J Prev Cardiol 2012; 21(7): 806-12
79. [79] Pussinen PJ, Sarna S, Puolakkainen M, Ohlin H, Sorsa T, Pesonen E. The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence. Int J Cardiol 2013; 167(2): 362-8
80. [80] Smith FB, Fowkes FG, Rumley A, Lee AJ, Lowe GD, Hau CM. Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh Artery Study. Eur Heart J 2000; 21(19): 1607-13
81. [81] Lindberg S, Pedersen SH, Mogelvang R, et al. Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2012; 60(4): 339-45
82. [82] Daniels LB, Barrett-Connor E, Clopton P, Laughlin GA, Ix JH, Maisel AS. Plasma neutrophil gelatinase-associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults: The Rancho Bernardo Study. J Am Coll Cardiol 2012; 59(12): 1101-9
83. [83] Cheng JM, Akkerhuis KM, Meilhac O, et al. Circulating osteoglycin and NGAL/MMP9 complex concentrations predict 1-year major adverse cardiovascular events after coronary angiography. Arterioscler Thromb Vasc Biol 2014; 34(5): 1078-84.
84. [84] Joseph G, Tarnow L, Astrup AS, et al. Plasma alpha-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patients. J Clin Endocrinol Metab 2008; 93(4): 1470-5
85. [85] Herman MP, Sukhova GK, Libby P, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001; 104(16): 1899-904
86. [86] Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999; 99(19): 2503-9
87. [87] Hasty KA, Jeffrey JJ, Hibbs MS, Welgus HG. The collagen substrate specificity of human neutrophil collagenase. J Biol Chem 1987; 262(21): 10048-52.
88. [88] Dorweiler B, Torzewski M, Dahm M, Kirkpatrick CJ, Lackner KJ, Vahl CF. Subendothelial infiltration of neutrophil granulocytes and liberation of matrix-destabilizing enzymes in an experimental model of human neo-intima. Thromb Haemost 2008; 99(2): 373-81
89. [89] Wu YW, Kao HL, Chen MF, et al. Characterization of plaques using 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1. J Nucl Med 2007; 48(2): 227-33
90. [90] Kato R, Momiyama Y, Ohmori R, Taniguchi H, Nakamura H, Ohsuzu F. Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. Circ J 2005; 69(9): 1035-40
91. [91] Turu MM, Krupinski J, Catena E, et al. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis 2006; 187(1): 161-9
92. [92] Momiyama Y, Ohmori R, Tanaka N, et al. High plasma levels of matrix metalloproteinase-8 in patients with unstable angina. Atherosclerosis 2010; 209(1): 206-10
93. [93] Peeters W, Moll FL, Vink A, et al. Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome. Eur Heart J 2011; 32(18): 2314-25
94. [94] Hwang JJ, Yang WS, Chiang FT, et al. Association of circulating matrix metalloproteinase-1, but not adiponectin, with advanced coronary artery disease. Atherosclerosis 2009; 204(1): 293-7
95. 95[] Lehrke M, Greif M, Broedl UC, et al. MMP-1 serum levels predict coronary atherosclerosis in humans. Cardiovasc Diabetol 2009; 8(50
96. [96] Abbas A, Aukrust P, Russell D, et al. Matrix metalloproteinase 7 is associated with symptomatic lesions and adverse events in patients with carotid atherosclerosis. PLoS One 2014; 9(1): e84935
97. [97] Dollery CM, Owen CA, Sukhova GK, Krettek A, Shapiro SD, Libby P. Neutrophil elastase in human atherosclerotic plaques: production by macrophages. Circulation 2003; 107(22): 2829-36
98. [98] Henriksen PA, Sallenave JM. Human neutrophil elastase: mediator and therapeutic target in atherosclerosis. Int J Biochem Cell Biol 2008; 40(6-7): 1095-100
99. [99] Amaro A, Gude F, Gonzalez-Juanatey R, et al. Plasma leukocyte elastase concentration in angiographically diagnosed coronary artery disease. Eur Heart J 1995; 16(5): 615-22
100. [100] Zureik M, Robert L, Courbon D, Touboul PJ, Bizbiz L, Ducimetiere P. Serum elastase activity, serum elastase inhibitors, and occurrence of carotid atherosclerotic plaques: the Etude sur le Vieillissement Arteriel (EVA) study. Circulation 2002; 105(22): 2638-45
101. [101] Dinerman JL, Mehta JL, Saldeen TG, et al. Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. J Am Coll Cardiol 1990; 15(7): 1559-63
102. [102] Leclercq A, Houard X, Philippe M, et al. Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J Leukoc Biol 2007; 82(6): 1420-9
103. [103] Hemdahl AL, Gabrielsen A, Zhu C, et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 2006; 26(1): 136-42
104. [104] Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94(1): 437-44
105. [105] Malle E, Waeg G, Schreiber R, Grone EF, Sattler W, Grone HJ. Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem 2000; 267(14): 4495-503
106. [106] Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. Jama 2001; 286(17): 2136-42
107. [107] Meuwese MC, Stroes ES, Hazen SL, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery diseasein apparently healthy individuals: the EPIC-Norfolk ProspectivePopulation Study. J Am Coll Cardiol 2007; 50(2): 159-65
108. 108[] Tavora FR, Ripple M, Li L, Burke AP. Monocytes and neutrophilsexpressing myeloperoxidase occur in fibrous caps and thrombi inunstable coronary plaques. BMC Cardiovasc Disord 2009; 9(27
109. [109] Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG.Myeloperoxidase: a useful biomarker for cardiovascular diseaserisk stratification? Clin Chem 2009; 55(8): 1462-70
110. [110] Rana JS, Arsenault BJ, Despres JP, et al. Inflammatory biomarkers,physical activity, waist circumference, and risk of future coronaryheart disease in healthy men and women. Eur Heart J 2011; 32(3):336-44
111. [111] Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serumlevels predict risk in patients with acute coronary syndromes.Circulation 2003; 108(12): 1440-5
112. 112[] Morrow DA, Sabatine MS, Brennan ML, et al. Concurrentevaluation of novel cardiac biomarkers in acute coronarysyndrome: myeloperoxidase and soluble CD40 ligand and the riskof recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008; 29(9): 1096-102
113. [113] Wong ND, Gransar H, Narula J, et al. Myeloperoxidase, subclinicalatherosclerosis, and cardiovascular disease events. JACCCardiovasc Imaging 2009; 2(9): 1093-9
114. [114] Heslop CL, Frohlich JJ, Hill JS. Myeloperoxidase and C-reactiveprotein have combined utility for long-term prediction ofcardiovascular mortality after coronary angiography. J Am CollCardiol 2010; 55(11): 1102-9
115. [115] Roman RM, Camargo PV, Borges FK, Rossini AP, Polanczyk CA.Prognostic value of myeloperoxidase in coronary artery disease:comparison of unstable and stable angina patients. Coron ArteryDis 2010; 21(3): 129-36
116. [116] Tang WH, Wu Y, Nicholls SJ, Hazen SL. Plasma myeloperoxidasepredicts incident cardiovascular risks in stable patients undergoingmedical management for coronary artery disease. Clin Chem 2011;57(1): 33-9
117. [117] Nicholls SJ, Tang WH, Brennan D, et al. Risk prediction withserial myeloperoxidase monitoring in patients with acute chestpain. Clin Chem 2011; 57(12): 1762-70
118. [118] Karakas M, Koenig W, Zierer A, et al. Myeloperoxidase isassociated with incident coronary heart disease independently oftraditional risk factors: results from the MONICA/KORAAugsburg study. J Intern Med 2012; 271(1): 43-50
119. [119] Haslacher H, Perkmann T, Gruenewald J, et al. Plasmamyeloperoxidase level and peripheral arterial disease. Eur J ClinInvest 2012; 42(5): 463-9
120. [120] Vuilleumier N, Montecucco F, Spinella G, et al. Serum levels ofanti-apolipoprotein A-1 auto-antibodies and myeloperoxidase aspredictors of major adverse cardiovascular events after carotidendarterectomy. Thromb Haemost 2013; 109(4): 706-15
121. [121] Corban MT, Eshtehardi P, Suo J, et al. Combination of plaqueburden, wall shear stress, and plaque phenotype has incrementalvalue for prediction of coronary atherosclerotic plaque progressionand vulnerability. Atherosclerosis 2014; 232(2): 271-6
122. 122[] Wentzel JJ, Schuurbiers JC, Gonzalo Lopez N, et al. In vivoassessment of the relationship between shear stress and necroticcore in early and advanced coronary artery disease.EuroIntervention 2013; 9(8): 989-95; discussion 95
123. [123] Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaqueformation and rupture. Circ Res 2014; 114(12): 1852-66
124. [124] Martinet W, Schrijvers DM, De Meyer GR. Necrotic cell death inatherosclerosis. Basic Res Cardiol 2011; 106(5): 749-60
125. [125] Brinkmann V, Reichard U, Goosmann C, et al. Neutrophilextracellular traps kill bacteria. Science 2004; 303(5663): 1532-5
126. [126] Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophilsdie to make NETs. Nat Rev Microbiol 2007; 5(8): 577-82
127. [127] Yipp BG, Kubes P. NETosis: how vital is it? Blood 2013; 122(16):2784-94
128. [128] Doring Y, Weber C, Soehnlein O. Footprints of neutrophilextracellular traps as predictors of cardiovascular risk. ArteriosclerThromb Vasc Biol 2013; 33(8): 1735-6
129. [129] Borissoff JI, Joosen IA, Versteylen MO, et al. Elevated levels ofcirculating DNA and chromatin are independently associated withsevere coronary atherosclerosis and a prothrombotic state.Arterioscler Thromb Vasc Biol 2013; 33(8): 2032-40
130. [130] Schauer C, Janko C, Munoz LE, et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med 2014; 20(5): 511-7
131. [131] Tolani S, Pagler TA, Murphy AJ, et al. Hypercholesterolemia and reduced HDL-C promote hematopoietic stem cell proliferation and monocytosis: studies in mice and FH children. Atherosclerosis 2013; 229(1): 79-85
132. [132] Vuilleumier N, Bas S, Pagano S, et al. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2010; 62(9): 2640-50
133. 133[] Quercioli A, Montecucco F, Galan K, et al. Anti-apolipoprotein A-1 IgG levels predict coronary artery calcification in obese but otherwise healthy individuals. Mediators Inflamm 2012; 2012(243158
134. [134] Falk E, Schwartz SM, Galis ZS, Rosenfeld ME. Putative murine models of plaque rupture. Arterioscler Thromb Vasc Biol 2007; 27(4): 969-72
135. [135] Kapourchali FR, Surendiran G, Chen L, Uitz E, Bahadori B, Moghadasian MH. Animal models of atherosclerosis. World J Clin Cases 2014; 2(5): 126-32
136. [136] Najafi AH, Aghili N, Tilan JU, et al. A new murine model of stress-induced complex atherosclerotic lesions. Dis Model Mech 2013; 6(2): 323-31
137. [137] Chen YC, Bui AV, Diesch J, et al. A novel mouse model of atherosclerotic plaque instability for drug testing and mechanistic/therapeutic discoveries using gene and microRNA expression profiling. Circ Res 2013; 113(3): 252-65
138. [138] Gomes Quindere AL, Benevides NM, Carbone F, Mach F, Vuilleumier N, Montecucco F. Update on selective treatments targeting neutrophilic inflammation in atherogenesis and atherothrombosis. Thromb Haemost 2014; 111(4): 634-46
139. [139] Barthel SR, Gavino JD, Descheny L, Dimitroff CJ. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets 2007; 11(11): 1473-91
140. [140] Bourdillon MC, Randon J, Barek L, et al. Reduced atherosclerotic lesion size in P-selectin deficient apolipoprotein E-knockout mice fed a chow but not a fat diet. J Biomed Biotechnol 2006; 2006(2): 49193
141. [141] van Leeuwen M, Gijbels MJ, Duijvestijn A, et al. Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR-/- mice. Arterioscler Thromb Vasc Biol 2008; 28(1): 84-9
142. [142] Rozenberg I, Sluka SH, Mocharla P, et al. Deletion of L-selectin increases atherosclerosis development in ApoE-/- mice. PLoS One 2011; 6(7): e21675
143. [143] Kling D, Stucki C, Kronenberg S, et al. Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studies. Thromb Res 2013; 131(5): 401-10.
144. [144] Chelliah R, Lucking AJ, Tattersall L, et al. P-selectin antagonism reduces thrombus formation in humans. J Thromb Haemost 2009; 7(11): 1915-9
145. [145] Luo W, Wang H, Ohman MK, et al. P-selectin glycoprotein ligand-1 deficiency leads to cytokine resistance and protection against atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis 2012; 220(1): 110-7
146. [146] Park JG, Ryu SY, Jung IH, et al. Evaluation of VCAM-1 antibodies as therapeutic agent for atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2013; 226(2): 356-63
147. [147] Wolf D, Hohmann JD, Wiedemann A, et al. Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis--but does not affect immunity and thrombosis in mice. Circ Res 2011; 109(11): 1269-79
148. [148] de Jager SC, Bot I, Kraaijeveld AO, et al. Leukocyte-specific CCL3 deficiency inhibits atherosclerotic lesion development by affecting neutrophil accumulation. Arterioscler Thromb Vasc Biol 2013; 33(3): e75-83
149. [149] Zernecke A, Weber C. Chemokines in atherosclerosis: proceedings resumed. Arterioscler Thromb Vasc Biol 2014; 34(4): 742-50
150. [150] Nencioni A, da Silva RF, Fraga-Silva RA, et al. Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice. Thromb Haemost 2014; 111(2): 308-22
151. 151[] I) EoMoMFiOSP. ClinicalTrials.gov: NCT01133210. https://clinicaltrials.gov/ct2/show/NCT01133210?term=maraviroc &rank=1
152. [152] Cipriani S, Francisci D, Mencarelli A, et al. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation 2013; 127(21): 2114-24
153. [153] Veillard NR, Kwak B, Pelli G, et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004; 94(2): 253-61
154. [154] van Wanrooij EJ, Happe H, Hauer AD, et al. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25(12): 2642-7
155. 155[] Sullivan TJ, Dairaghi DJ, Krasinski A, et al. Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications. J Pharmacol Exp Ther 2012. [Epub ahead of print]
156. [156] Fraga-Silva RA, Savergnini SQ, Montecucco F, et al. Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques. Thromb Haemost 2014; 111(4): 736-47
157. [157] Montecucco F, Lenglet S, Braunersreuther V, et al. Single administration of the CXC chemokine-binding protein Evasin-3 during ischemia prevents myocardial reperfusion injury in mice. Arterioscler Thromb Vasc Biol 2010; 30(7): 1371-7
158. [158] Braunersreuther V, Montecucco F, Pelli G, et al. Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice. Thromb Haemost 2013; 110(4): 807-25
159. [159] Montecucco F, Mach F, Lenglet S, et al. Treatment with Evasin-3 abrogates neutrophil-mediated inflammation in mouse acute pancreatitis. Eur J Clin Invest 2014, 44(10): 940-50
160. [160] Copin JC, da Silva RF, Fraga-Silva RA, et al. Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice. J Cereb Blood Flow Metab 2013; 33(4): 490-8
161. [161] Carbone F, Mach F, Vuilleumier N, Montecucco F. Cannabinoid receptor type 2 activation in atherosclerosis and acute cardiovascular diseases. Curr Med Chem 2014, 21(35):4046-58
162. [162] Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005; 434(7034): 782-6
163. [163] Montecucco F, Di Marzo V, da Silva RF, et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J 2012; 33(7): 846-56
164. [164] Carbone F, Nencioni A, Mach F, Vuilleumier N, Montecucco F. Pathophysiological role of neutrophils in acute myocardial infarction. Thromb Haemost 2013; 110(3): 501-14
165. [165] Chevre R, Gonzalez-Granado JM, Megens RT, et al. High-resolution imaging of intravascular atherogenic inflammation in live mice. Circ Res 2014; 114(5): 770-9
166. [166] Muller A, Mu L, Meletta R, et al. Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules. Int J Cardiol 2014; 174(3): 503-15.